Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

NCT02844816 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02844816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02844816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
March 13, 2017
Completion date
June 26, 2024
Enrollment
172 (actual)
Sites
272

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent bladder urothelial carcinoma, stage 0a bladder urothelial carcinoma ajcc v6 and v7, stage 0is bladder urothelial carcinoma ajcc v6 and v7, stage i bladder urothelial carcinoma ajcc v6 and v7